Does SGLT2-inhibitor therapy reduce the occurrence of acute kidney injury in diabetic patients with CKD and severe aortic stenosis undergoing TAVI?
SGLT2-inhibitors may offer a nephroprotective effect, reducing the risk of acute kidney injury in high-risk diabetic patients with CKD undergoing TAVI.
In diabetic patients with CKD undergoing TAVI, SGLT2i therapy was associated with a lower occurrence of AKI compared to those not treated with SGLT2i, suggesting a potential nephroprotective effect in this high-risk population.
Paolisso et al. (Wed,) studied this question.